Brief: Annexin Pharmaceuticals Q2 2026 Net Loss SEK 11.6 Mln
21/08/2026 07:36
BRIEF-Annexin Pharmaceuticals Q2 2026 Net Loss SEK 11.6 Mln Aug 21 (Reuters) - Annexin Pharmaceuticals AB (publ) ANNX.ST:
Q2 2026 NET LOSS AMOUNTED TO -11,557 TSEK
Q2 2026 OPERATING CASH FLOW AMOUNTED TO -11,461 TSEK
Source text: ID:nMFNt7H0g
Further company coverage: ANNX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Annexin Pharmaceuticals AB (publ)
See all newsBrief: Annexin Pharmaceuticals Q3 Net Loss At SEK 9.5 Mln
Brief: Annexin Pharmaceuticals Q2 2026 Net Loss SEK 11.6 Mln
Brief: Annexin Pharmaceuticals Gets International Nonproprietary Name Drug Candidate Anxv
Brief: Annexin Pharmaceuticals Updates On Nine Patients Treated In Nexus Study
Brief: Annexin's Rights Issue 98% Subscribed